The Priority Review

Clinical trials

Mean BMI change was -6.7% on liraglutide in children with obesity at week 56

Mean BMI change at week 56 was -6.7% with liraglutide and 2.1% with placebo. Research teams now have main-phase outcome and safety data from a trial of 82 children aged 6 to below 12 years.

Machine-summarized from the primary sources listed below; not independently reported. How we use automation

Mean relative change in body mass index (BMI) at week 56 was -6.7% with liraglutide and 2.1% with placebo in children with obesity, the study record shows. Novo Nordisk's randomized Phase 3 study now has main-phase outcome and safety data for a trial that enrolled 82 children aged 6 to below 12 years.

Children reaching a BMI reduction at week 56 Percentage achieving at least a 5% or at least a 10% reduction in baseline BMI at week 56 0% 10% 20% 30% 40% 50% Percent of participants with available data Liraglutide at least 5% reduction (n = 52) 46.2% Placebo at least 5% reduction (n = 23) 8.7% Liraglutide at least 10% reduction (n = 52) 34.6% Placebo at least 10% reduction (n = 23) 4.3% Secondary outcomes use 52 liraglutide participants and 23 placebo participants with available data. The liraglutide group received 3.0 mg or the individual maximum tolerated dose. From the study record NCT04775082, results first posted November 16, 2026. The Priority Review.
Children reaching a BMI reduction at week 56 Percentage achieving at least a 5% or at least a 10% reduction in baseline BMI at week 56 0% 10% 20% 30% 40% 50% Percent of participants with available data Liraglutide at least 5% reduction (n = 52) 46.2% Placebo at least 5% reduction (n = 23) 8.7% Liraglutide at least 10% reduction (n = 52) 34.6% Placebo at least 10% reduction (n = 23) 4.3% Secondary outcomes use 52 liraglutide participants and 23 placebo participants with available data. The liraglutide group received 3.0 mg or the individual maximum tolerated dose. From the study record NCT04775082, results first posted November 16, 2026. The Priority Review.

Why it matters

SAXENDA, which contains liraglutide, is indicated with a reduced calorie diet and increased physical activity for adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, the supplied prescribing information states. The label says safety and effectiveness have not been established in patients less than 12 years of age. The study examines weight management and safety in children below that age, with counseling about food choices and physical activity alongside study treatment, the study record states.

Relative change in BMI

November 16, 2026, is the results-first-posted date. The primary outcome measures relative change in BMI from baseline to week 56 during the in-trial period, defined as the uninterrupted interval from randomization to the last contact with the study site, the record states.

The primary outcome table includes participants with available data, analyzed according to planned treatment. It lists:

  • Liraglutide 3.0 mg: 52 participants, mean BMI change -6.7%, standard deviation 9.6.
  • Placebo: 23 participants, mean BMI change 2.1%, standard deviation 6.1.

For percentage change in BMI, the model-based treatment difference under the treatment policy estimand was -7.40, with a 95% confidence interval from -11.56 to -3.24 and a p-value of 0.0005, the record reports. That analysis used baseline BMI and factors including randomized treatment, gender, Tanner stage and the interaction between the stratification groups.

Body weight and BMI reduction

Mean relative body weight change at week 56 was 0.4% with liraglutide and 10.2% with placebo, with standard deviations of 10.7 and 6.8, respectively, the record reports. The corresponding mean changes in body weight were 0.1 kg and 7.5 kg, with standard deviations of 8.2 and 5.3.

The percentage achieving at least a 5% reduction in baseline BMI at week 56 was 46.2% with liraglutide and 8.7% with placebo. At least a 10% reduction was recorded for 34.6% and 4.3%, respectively, the record shows. These secondary outcome tables also use 52 liraglutide participants and 23 placebo participants with available data.

Treatment and follow-up

The main phase included a 12-week run-in with diet and physical activity counseling, 56 weeks of treatment and 26 weeks of follow-up. Participants received a daily subcutaneous injection, with weekly dose escalation to 3.0 mg or the individual maximum tolerated dose in the liraglutide group, the study record states.

The participant-flow table lists 56 children starting liraglutide and 26 starting placebo. It records completion for 44 and 22, respectively. An adverse event was the reason for noncompletion for 6 liraglutide participants and 0 placebo participants, the record reports.

Safety

The safety population included all randomized participants exposed to at least one dose, grouped by actual treatment. Serious adverse events affected 7 of 56 liraglutide participants and 2 of 26 placebo participants; deaths were 0 in each group, the adverse-event table shows. The table covers baseline through week 82. It includes events beginning between the first dose and the earliest of 14 days after the last dose, the first follow-up visit for participants who discontinued treatment, or the last study visit for participants withdrawn without follow-up.

What remains uncertain

The submitted results cover the main phase. Extension-phase data are reserved for an update at study completion, the record states.

Sources